AR119677A1 - Dominios de unión anti-cd38 - Google Patents

Dominios de unión anti-cd38

Info

Publication number
AR119677A1
AR119677A1 ARP200100174A ARP200100174A AR119677A1 AR 119677 A1 AR119677 A1 AR 119677A1 AR P200100174 A ARP200100174 A AR P200100174A AR P200100174 A ARP200100174 A AR P200100174A AR 119677 A1 AR119677 A1 AR 119677A1
Authority
AR
Argentina
Prior art keywords
binding domains
composition
nucleic acids
multiple myeloma
acids encoding
Prior art date
Application number
ARP200100174A
Other languages
English (en)
Inventor
Erin Willert
Eric Poma
Vinay Bhaskar
Mary Haak-Frendscho
Andrew Walling Drake
Wouter Korver
Shweta Singh
Gregory Landes
Kathleen Ann Elias
Nibedita Chattopadhyay
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR119677A1 publication Critical patent/AR119677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Gas Separation By Absorption (AREA)
  • Finish Polishing, Edge Sharpening, And Grinding By Specific Grinding Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente descripción, se proporcionan dominios de unión anti-CD38, una composición que comprende los dominios de unión anti-CD38, ácidos nucleicos que codifican los dominios de unión anti-CD38 y un método de uso de los dominios de unión anti-CD38 o la composición para tratar el mieloma múltiple.
ARP200100174A 2019-01-23 2020-01-23 Dominios de unión anti-cd38 AR119677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962795855P 2019-01-23 2019-01-23

Publications (1)

Publication Number Publication Date
AR119677A1 true AR119677A1 (es) 2022-01-05

Family

ID=69740548

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100174A AR119677A1 (es) 2019-01-23 2020-01-23 Dominios de unión anti-cd38

Country Status (9)

Country Link
US (2) US11414496B2 (es)
EP (1) EP3914358A1 (es)
JP (1) JP2022518282A (es)
CN (1) CN113710324A (es)
AR (1) AR119677A1 (es)
AU (1) AU2020211407A1 (es)
CA (1) CA3127624A1 (es)
TW (1) TW202043281A (es)
WO (1) WO2020154540A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3914358A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
CN113454108A (zh) 2019-01-23 2021-09-28 米伦纽姆医药公司 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
WO2023172983A1 (en) * 2022-03-08 2023-09-14 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
EP1490677A4 (en) 2002-02-27 2006-01-18 California Inst Of Techn COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US7230068B2 (en) 2003-10-09 2007-06-12 Ambrx, Inc. Polymer derivatives
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
SI3604333T1 (sl) 2014-03-11 2021-08-31 Molecular Templates, Inc. Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
PT3303373T (pt) 2015-05-30 2020-07-14 Molecular Templates Inc Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas
CN113454108A (zh) 2019-01-23 2021-09-28 米伦纽姆医药公司 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白
EP3914358A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies

Also Published As

Publication number Publication date
CA3127624A1 (en) 2020-07-30
CN113710324A (zh) 2021-11-26
TW202043281A (zh) 2020-12-01
US20200231696A1 (en) 2020-07-23
US11414496B2 (en) 2022-08-16
EP3914358A1 (en) 2021-12-01
AU2020211407A1 (en) 2021-08-12
WO2020154540A1 (en) 2020-07-30
JP2022518282A (ja) 2022-03-14
US20230203186A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
AR119677A1 (es) Dominios de unión anti-cd38
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CO2021006301A2 (es) Composiciones y métodos de inmunoterapia
UY37523A (es) Anticuerpos anti-ox40 y sus usos
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
BR112019012342A2 (pt) anticorpos il-11
CL2018003267A1 (es) Cápsulas que comprenden bencilpropargiléteres para usar como inhibidores de la nitrificación.
AR115599A1 (es) Método y aparato para la preparación de un bien de ensilado y proceso de ensilaje
CL2021002262A1 (es) Composiciones y métodos para tratar laminopatías
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
MY187381A (en) Methods, compositions and uses relating thereto
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CO2023015915A2 (es) Anticuerpos anti-ccr8
CU20220019A7 (es) Proteínas de fusión nkg2d
UY38472A (es) Moduladores de la expresión de foxp3
BR112019004639A2 (pt) formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas
CL2021002423A1 (es) Un novedoso compuesto derivado de alulosa

Legal Events

Date Code Title Description
FB Suspension of granting procedure